Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC

Autor: Saw, Stephanie P.L. a, b, ⁎, Low, Yi Fen a, Lai, Gillianne G.Y. a, b, Chan, Landon L. c, Wong, Wesley K.Y. d, Tsui, Giselle d, Chen, Olivia H. d, Seet, Amanda O.L. a, b, Tan, Wei Chong a, b, Tan, Aaron C. a, b, Chan, Johan W.K. a, b, Teh, Yi Lin a, b, Tan, Wan-Ling a, b, Ng, Quan Sing a, b, Ang, Mei-Kim a, b, Kanesvaran, Ravindran a, b, Lim, Darren W.T. a, b, Tan, Daniel S.W. a, b, Mok, Tony S.K. c, Li, Molly S.C. c
Zdroj: In Lung Cancer July 2024 193
Databáze: ScienceDirect
Externí odkaz: